Mallinckrodt plc Stock News

Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, today announced publication of findings from a medical chart study to assess the real-world use of terlipressin and other vasopressors

Mallinckrodt (MNK) completes the rolling submission of a BLA for StrataGraft regenerative skin tissue to treat adults with deep partial-thickness thermal burns

Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, today announced that Stratatech, a Mallinckrodt company, has completed its rolling submission of a Biologics License Application (BLA)

Mallinckrodt (MNK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Investors need to pay close attention to Mallinckrodt (MNK) stock based on the movements in the options market lately.

Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, announced today that it will appeal a ruling by the U.S. District Court for the District of Columbia in a lawsuit filed by its subsidi

Frequently, buying stocks trading below their fundamental net worth can yield lucrative rewards for investors.

U.S. stocks lost ground in the final hour of trade Tuesday, reversing earlier gains, following at a critical report of Moderna’s vaccine candidate and congressional testimony on progress toward deli

Indiscriminate sell-offs can sometimes lead to opportunities the crowds have missed. Here are three stocks that fit the criteria.